摘要
目的探讨急性冠脉综合征(ACS)患者厄贝沙坦治疗前后血巨噬细胞炎性蛋白1α(MIP-1α)、血栓调节蛋白(TM)、血小板活化因子(PAF)及可溶性CD40配体(sCD40L)水平及临床意义。方法采用ELISA法测定86例ACS患者、52例健康对照者血清中MIP-1α、TM、PAF及sCD40L浓度,ACS患者随机分常规(40例)和厄贝沙坦(46例)治疗组,治疗8周后再次测定血MIP-1α、TM、PAF及sCD40L含量。结果血MIP-1α、TM、PAF和sCD40L水平ACS组明显高于对照组(P<0.05),ACS患者治疗8周后MIP-1α、TM、PAF和sCD40L水平均明显下降(P<0.05),且厄贝沙坦组下降明显(P<0.05)。结论 ACS的发生与MIP-1α、TM、PAF和sCD40L有关,厄贝沙坦可降低血MIP-1α、TM、PAF和sCD40L水平,在抑制动脉粥样病变的炎症反应,保护血管内皮方面有一定作用。
Objective To observe the changes of macrophage inflammatory protein-1α（MIP-1α） and thrombomodulin（TM） and platelet activating factor（PAF） and soluble CD40 ligand in patients with acute coronary syndrome（ACS） before and after Irbesartan therapy and its clinical significance.Methods MIP-1α,TM,PAF and sCD40L were determined by enzyme-linked immunosorbent assay（ELISA） in 86 cases of ACS patients and 52 health controls;then ACS patients were divided into the conventional therapy group（40 cases） and Irbesartan treatment group（46 cases）,MIP-1α and TM and PAF and sCD40L were again detected by ELISA after 8 weeks treatment.Results Serum MIP-1α,TM,PAF and sCD40L levels of ACS patients were significantly higher than that of healthy control group（P0.05）;after Irbesartan treatment of 8 weeks,MIP-1α,TM,PAF and sCD40L levels were significantly decreased（P0.05）,and Irbesartan group decreased significantly（P0.05）.Conclusion ACS occurrence may correlate with MIP-1α,TM,PAF and sCD40L,Irbesartan can reduce blood levels of MIP-1α,TM,PAF and sCD40L,inhibit the inflammatory response in atherosclerotic lesions,and protect the vascular endothelium.
出处
《中华全科医学》
2011年第11期1691-1692,共2页
Chinese Journal of General Practice
